Tempest Therapeutics Q3 net loss narrows as costs drop, continues strategic alternatives process

Tempest Therapeutics

05/11/2025 13:36

Overview

Tempest Therapeutics Q3 net loss narrows to $3.5 mln from $10.6 mln in 2024

Research and development expenses fell to $0.6 mln from $7.6 mln in Q3 2024

Company ended Q3 with $7.5 mln in cash, down from $30.3 mln at 2024 year-end

Outlook

Tempest continues strategic alternatives process to maximize stockholder value

Company anticipates TPST-1495 Phase 2 trial start with NCI collaboration

Tempest confident in amezalpat's potential for first-line HCC treatment

Result Drivers

STRATEGIC SHIFT - Co reduced R&D expenses by $7.0 mln as it re-prioritized efforts towards exploring strategic alternatives

CASH DECREASE - Cash and cash equivalents fell to $7.5 mln from $30.3 mln at 2024 year-end, mainly due to operating activities

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.79
Q3 Net Income
-$3.51 mln
Q3 Operating Income
-$3.59 mln


Analyst Coverage

The one available analyst rating on the shares is "hold"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Press Release: ID:nGNX4XRww0

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)